Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens.
Vascular endothelial growth factor (VEGF) is an angiogenic protein proposed to be an important biomarker for the prediction of tumour growth and disease progression. Recent studies suggest that VEGF measurements in biospecimens, including urine, may have predictive value across a range of cancers. However, the reproducibility and reliability of urinary VEGF measurements have not been determined. We collected urine samples from patients receiving radiation treatment for glioblastoma multiforme (GBM) and examined the effects of five variables on measured VEGF levels using an ELISA assay. To quantify the factors affecting the precision of the assay, two variables were examined: the variation between ELISA kits with different lot numbers and the variation between different technicians. Three variables were tested for their effects on measured VEGF concentration: the time the specimen spent at room temperature prior to assay, the addition of protease inhibitors prior to specimen storage and the alteration of urinary pH. This study found that VEGF levels were consistent across three different ELISA kit lot numbers. However, significant variation was observed between results obtained by different technicians. VEGF concentrations were dependent on time at room temperature before measurement, with higher values observed 3-7 hrs after removal from the freezer. No significant difference was observed in VEGF levels with the addition of protease inhibitors, and alteration of urinary pH did not significantly affect VEGF measurements. In conclusion, this determination of the conditions necessary to reliably measure urinary VEGF levels will be useful for future studies related to protein biomarkers and disease progression.
Kirk
M J
MJ
Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-1002, USA.
Hayward
R M
RM
Sproull
M
M
Scott
T
T
Smith
S
S
Cooley-Zgela
T
T
Crouse
N S
NS
Citrin
D E
DE
Camphausen
K
K
D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D017056:Medical Laboratory Personnel; D011480:Protease Inhibitors / Q000494:pharmacology; D015203:Reproducibility of Results; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000652:urine*
D011480:Protease Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
Cancer Res. 1998 Apr 1;58(7):1395-9
9537238
Crit Rev Clin Lab Sci. 2001 Jun;38(3):225-62
11451209
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Mikrobiyol Bul. 2006 Oct;40(4):445-6
17205704
J Clin Oncol. 2004 Feb 1;22(3):499-506
14752073
J Clin Oncol. 2001 Feb 15;19(4):1207-25
11181687
J Immunol Methods. 1992 Jun 24;150(1-2):111-9
1613248
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
J Clin Oncol. 2005 Feb 1;23(4):792-9
15681523
Clin Ther. 2006 Nov;28(11):1779-802
17212999
J Clin Oncol. 2005 May 20;23(15):3502-8
15908660
Urology. 2001 Apr;57(4):675-9
11306379
Clin Cancer Res. 2000 May;6(5):1854-64
10815908
Kidney Int. 2006 Apr;69(8):1471-6
16501490
Clin Chem. 1999 Mar;45(3):430-2
10053054
Eur J Cancer. 1998 Dec;34(13):2041-5
10070308
IARC Sci Publ. 1997;(142):223-36
9354922
Cancer Res. 2000 Jun 1;60(11):2898-905
10850435
Ann Surg. 2003 Jul;238(1):9-28
12832961
Biochemistry. 2005 Nov 8;44(44):14409-18
16262241
J Clin Oncol. 2004 Mar 1;22(5):777-84
14990632